SS-31 Dosing Chart: Common Research Doses and Protocol Basics

An SS-31 dosing chart is a quick-reference table that lists the amounts of the peptide SS-31 (elamipretide) used in published research, usually expressed as milligrams per kilogram, milligrams per day, or milligrams per kilogram per hour. Human trials have centered on roughly 0.05–0.25 mg/kg/hr by intravenous infusion and 40 mg per day by subcutaneous injection, while rodent studies often use 1–5 mg/kg per day. No SS-31 product is FDA-approved for human use, so any chart you find online is a research summary, not a prescription.

What SS-31 Is and Why Dosing Gets Complicated

SS-31 is a synthetic tetrapeptide also known as elamipretide, MTP-131, and Bendavia. It is designed to accumulate in mitochondria and bind cardiolipin on the inner mitochondrial membrane. Because the compound is still experimental, every number on a chart traces back to a specific preclinical model or clinical trial protocol.

Dosing is complicated by three factors: the peptide has a short half-life, it is not orally bioavailable, and human studies have used more than one route of administration. A subcutaneous dose and an intravenous infusion dose are not interchangeable, even when they look similar on paper.

SS-31 Dosing Chart: Human Trials vs. Preclinical Studies

The table below summarizes doses reported in peer-reviewed literature. It exists to help researchers compare study designs, not to guide self-administration.

Study type	Route	Reported dose	Frequency	Notes
Human trial (Barth syndrome, primary mitochondrial myopathy)	Subcutaneous	40 mg per day	Once daily	Flat dose, not weight-based
Human trial (heart failure)	IV infusion	0.05–0.25 mg/kg per hour	2–4 hour infusion	Protocol-dependent
Rodent study	Subcutaneous or intraperitoneal	1–5 mg/kg	Daily or every other day	Common in cardiac and renal injury models
Cell culture	Media addition	0.1–10 µM	Single or repeated	Not convertible to a human dose

The range is wide for a reason. A 5 mg/kg mouse dose cannot be copied into a human protocol without allometric scaling, and even a scaled estimate is a starting point for a study rather than a validated human dose.

How to Read an SS-31 Dosing Table Correctly

Weight-Based vs. Fixed Doses

Human SS-31 research has used both formats. Subcutaneous programs often rely on a flat 40 mg per day, while infusion programs use mg/kg/hr. Mixing the two formats is one of the most common mistakes when people compare an ss-31 dosage chart from one trial with data from another.

Concentration Is Not the Same as Dose

A vial labeled 10 mg is not a dose; it is a quantity of lyophilized powder that must be dissolved before use. The final concentration depends on how much diluent is added. The same vial mixed into 1 mL or 5 mL produces concentrations that differ by a factor of five.

If you are reviewing a lab plan, compare it against the ss-31 peptide dosing protocol described in the original paper rather than a blog summary. Small differences in infusion time, injection volume, and vehicle can change study results.

Reconstitution and Storage Reference

Vial size	Diluent volume	Final concentration	Storage
5 mg	1 mL	5 mg/mL	Refrigerate, protect from light
10 mg	2 mL	5 mg/mL	Refrigerate, protect from light
10 mg	1 mL	10 mg/mL	Refrigerate, follow label guidance
50 mg	5 mL	10 mg/mL	Refrigerate, follow label guidance

Freeze-dried peptide is generally stable at -20 °C. Once reconstituted, solution should be refrigerated and used within the period stated on the certificate of analysis. Repeated freeze-thaw cycles can degrade the peptide and skew results.

Many labs also track an ss-31 peptide dosage log that records vial lot number, reconstitution date, and final concentration. That habit makes it easier to reproduce a study later.

SS-31 vs. Other Research Peptides

SS-31 is often discussed alongside other mitochondrial and metabolic peptides, but the compounds are not interchangeable. Researchers comparing fat-loss peptides sometimes review an aod-9604 peptide dosing chart next to SS-31 data, even though AOD-9604 targets lipolysis signaling and SS-31 targets mitochondrial cardiolipin.

Weighing one peptide's numbers against another's only makes sense when route, vehicle, and study species match. Otherwise the comparison is misleading.

Older papers sometimes spell the compound without a hyphen, so a search for ss 31 dosing protocol can surface the same studies. Checking the DOI, not just the wording, is the reliable way to confirm you are looking at the right molecule.

Safety, Legal Status, and Practical Takeaways

SS-31 is not FDA-approved for human use in the United States. Products sold online are labeled for research purposes only and are not intended for human consumption.

In clinical trials, reported side effects have included injection site reactions, headache, and nausea, though the full safety profile is still being characterized. Anyone considering SS-31 for any reason should consult a licensed healthcare professional first.

• Always match the dose format, whether mg/kg, mg/kg/hr, or flat mg, to the study you are citing.
• Do not convert cell culture concentrations directly into human doses.
• Record lot numbers, reconstitution dates, and concentrations for reproducibility.
• Treat every online SS-31 dosing chart as a research summary, not medical advice.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical SS-31 dose used in human studies?

Published human trials have used either a flat 40 mg subcutaneous dose once daily or an intravenous infusion of roughly 0.05–0.25 mg/kg per hour. Those numbers come from specific trial protocols and are not an approved dosing standard. SS-31, also called elamipretide, is not FDA-approved for human use.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the original research name for elamipretide, which is also known as MTP-131 and Bendavia. The names appear interchangeably in the scientific literature, so a dosing table labeled with any of these names may describe the same peptide.

Can I use an SS-31 dosing chart to dose myself?

No. Online SS-31 dosing charts summarize research, and products sold under that name are labeled for laboratory use only. There is no established safe human dose outside of supervised clinical trials, so anyone with a health concern should talk to a licensed healthcare professional instead of self-dosing.